Trial · NCT00435825
Adverse events144
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 144
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Pyrexia | General disorders | Peginterferon Alfa-2a 90 μg_24 Weeks | 40 | 144 | |
| other | Pyrexia | General disorders | Peginterferon Alfa-2a 180 μg_24 Weeks | 50 | 141 | |
| other | Pyrexia | General disorders | Peginterferon Alfa-2a 90 μg_48 Weeks | 43 | 132 | |
| other | Pyrexia | General disorders | Peginterferon Alfa-2a 180 μg_48 Weeks | 46 | 130 | |
| other | Fatigue | General disorders | Peginterferon Alfa-2a 90 μg_24 Weeks | 27 | 144 | |
| other | Fatigue | General disorders | Peginterferon Alfa-2a 180 μg_24 Weeks | 20 | 141 | |
| other | Fatigue | General disorders | Peginterferon Alfa-2a 90 μg_48 Weeks | 29 | 132 | |
| other | Fatigue | General disorders | Peginterferon Alfa-2a 180 μg_48 Weeks | 32 | 130 | |
| other | Malaise | General disorders | Peginterferon Alfa-2a 90 μg_24 Weeks | 1 | 144 | |
| other | Malaise | General disorders | Peginterferon Alfa-2a 180 μg_24 Weeks | 9 | 141 | |
| other | Malaise | General disorders | Peginterferon Alfa-2a 90 μg_48 Weeks | 8 | 132 | |
| other | Malaise | General disorders | Peginterferon Alfa-2a 180 μg_48 Weeks | 6 | 130 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Peginterferon Alfa-2a 90 μg_24 Weeks | 17 | 144 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Peginterferon Alfa-2a 180 μg_24 Weeks | 24 | 141 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Peginterferon Alfa-2a 90 μg_48 Weeks | 26 | 132 | |
| other | Alopecia | Skin and subcutaneous tissue disorders | Peginterferon Alfa-2a 180 μg_48 Weeks | 41 | 130 | |
| other | Rash | Skin and subcutaneous tissue disorders | Peginterferon Alfa-2a 90 μg_24 Weeks | 7 | 144 | |
| other | Rash | Skin and subcutaneous tissue disorders | Peginterferon Alfa-2a 180 μg_24 Weeks | 7 | 141 | |
| other | Rash | Skin and subcutaneous tissue disorders | Peginterferon Alfa-2a 90 μg_48 Weeks | 5 | 132 | |
| other | Rash | Skin and subcutaneous tissue disorders | Peginterferon Alfa-2a 180 μg_48 Weeks | 11 | 130 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00435825/events